The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. NF-kappaB pathway activators as potential ageing biomarkers: targets for new therapeutic strategies. ![]() Hum Reprod 2013 28: 750–761.īalistreri CR, Candore G, Accardi G, Colonna-Romano G, Lio D. miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells. Mol Interv 2008 8: 22–27.Ībe W, Nasu K, Nakada C, Kawano Y, Moriyama M, Narahara H. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Immunobiology 2009 214: 761–777.Īncrile BB, O'Hayer KM, Counter CM. Cellular and molecular pathways linking inflammation and cancer. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A. Multifaceted link between cancer and inflammation. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Natural innate and adaptive immunity to cancer. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Mantovani A, Allavena P, Sica A, Balkwill F. Inherited susceptibility to common cancers. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. Cancer Immunol Immunother 2009 58: 1919–1933.ĭong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach. N Engl J Med 2009 360: 1351–1354.Ĭaruso C, Balistreri CR, Candore G, Carruba G, Colonna-Romano G, Di Bona D et al. Screening for prostate cancer-the controversy that refuses to die. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Estimates of cancer incidence and mortality in Europe in 2008. World J Radiol 2012 4: 241–246.įerlay J, Parkin DM, Steliarova-Foucher E. Epidemiology of prostate cancer and treatment remarks. CA Cancer J Clin 2011 61: 69–90.Īrcangeli S, Pinzi V, Arcangeli G. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. ![]() Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Lin BK, Clyne M, Walsh M, Gomez O, Yu W, Gwinn M et al. Many of these aspects are summarized in this report through the elucidation of literature data and the results of our studies. Indeed, their identification may hold promise for the realization of a personalized PC medicine. Thus, their combinations might be used as promising biomarkers in a pre- and post-treatment clinical PC setting. Combinations of several inflammatory and sex steroid hormone pathway SNPs are found in PC patients. Single-nucleotide polymorphisms (SNPs) may operate in combination to create a ‘risk profile’. Accordingly, the research has particularly focused its attention on genetic variants in genes, codifying molecules of signaling innate immune/inflammatory and steroid metabolism pathways, which are able to modify the PC genetic susceptibility and clinical disease outcome. No adequate biomarkers exist until now to guide PC prognosis and treatment. Thus, chronic inflammation drives prostate carcinogenesis and neoplastic progression. infectious agents, dietary carcinogens) and hormonal imbalances has been reported to have a fundamental role in PC pathophysiology by evoking chronic inflammation. ![]() A complex interaction between genetic and environmental factors (i.e. Several pathologies affect human prostate, such as prostate cancer (PC), which is the most common non-skin malignant cancer in Western male populations.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |